Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib

Alexander Traxl, Severin Mairinger, Thomas Filip, Michael Sauberer, Johann Stanek, Stefan Poschner, Walter Jäger, Viktoria Zoufal, Gaia Novarino, Nicolas Tournier, Martin Bauer, Thomas Wanek, Oliver Langer

Publications: Contribution to journalArticlePeer Reviewed

Original languageEnglish
Pages (from-to)1282-1293
Number of pages12
JournalMolecular Pharmaceutics
Volume16
Issue number3
DOIs
Publication statusPublished - 4 Mar 2019

Austrian Fields of Science 2012

  • 301212 Clinical pharmacy

Keywords

  • ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors
  • ATP Binding Cassette Transporter, Subfamily G, Member 2/antagonists & inhibitors
  • Animals
  • Blood-Brain Barrier/metabolism
  • Brain/metabolism
  • Capillary Permeability/physiology
  • Cyclosporine/administration & dosage
  • Drug Interactions
  • Erlotinib Hydrochloride/administration & dosage
  • Female
  • Mice
  • Models, Animal
  • Positron-Emission Tomography/methods
  • Protein Kinase Inhibitors/administration & dosage
  • Quinolines/administration & dosage
  • Radiopharmaceuticals/administration & dosage
  • Solubility
  • Tissue Distribution
  • P-GLYCOPROTEIN
  • tyrosine kinase inhibitors
  • IN-VITRO
  • ERLOTINIB
  • CANCER RESISTANCE PROTEIN
  • blood-brain barrier
  • breast cancer resistance protein
  • [C-11]erlotinib
  • PENETRATION
  • SUBFAMILY-B MEMBER-1
  • P-glycoprotein
  • EFFLUX
  • TRANSPORT ACTIVITY
  • positron emission tomography
  • REVERSES MULTIDRUG-RESISTANCE
  • PET
  • [ C]erlotinib

Fingerprint

Dive into the research topics of 'Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib'. Together they form a unique fingerprint.

Cite this